GAMP 5 is guidance on how to validate, not a monster
GAMP 5 helps life sciences teams apply a risk-based approach to computerized systems. The goal is simple: the level of validation effort should match patient safety, product quality, and data integrity risk.
The part most teams miss
GAMP 5 does not demand exhaustive testing of everything. It encourages you to focus on critical functions and critical data, and to leverage supplier activities where appropriate.
Key ideas, simplified
1) Intended use drives scope. Define what the system does in your process, not what the vendor brochure claims.
2) Risk drives depth. High-risk workflows get deeper verification. Low-risk areas get lighter evidence, with rationale.
3) Supplier matters. A mature vendor with strong SDLC, testing, and transparency can reduce the amount you must independently recreate.
4) Configuration is logic. In modern platforms, your configuration choices can be as impactful as code. Control and verify them.
How this fits with Agile and SaaS
Think in small cycles. Each change gets a short impact assessment, targeted tests, and documented approval. You stay in a validated state by validating changes, not by doing periodic “big bang” revalidation.
A practical takeaway
If your team can explain intended use, show a risk assessment, and produce traceable evidence for critical controls, you are aligned with modern expectations. That is GAMP 5 in action, without the drama.
In recent years, validation processes across the pharmaceutical industry have been undergoing a major transformation. Workflows that were traditionally managed through paper documentation, spreadsheets and manual review cycles are increasingly moving toward digital validation platforms. As a result, life sciences organizations often evaluate solutions such as Kneat, Validfor, ValGenesis, MasterControl and Veeva when modernizing validation lifecycle management and compliance documentation.